Metabolomic profiling of hormone-dependent cancers: a bird's eye view

• Hormone-dependent cancers exhibit metabolic reprogramming.
• PCa exhibits metabolic alterations in polyamines, amino acids, and fatty acids.
• BCa displays reprogramming in glycine, serine, and choline metabolism.
• Therapeutic resistance is associated with altered lipid metabolism.

Hormone-dependent cancers present a significant public health challenge, because they are among the most common cancers in the world. One factor associated with cancer development and progression is metabolic reprogramming. By understanding these alterations, we can identify potential markers and novel biochemical therapeutic targets. Metabolic profiling is an advanced technology that allows investigators to assess low-molecular-weight compounds that reflect physiological alterations. Current research in metabolomics on prostate (PCa) and breast cancer (BCa) have made great strides in uncovering specific metabolic pathways that are associated with cancer development, progression, and resistance. In this review, we highlight some of the major findings and potential therapeutic advances that have been reported utilizing this technology.